NCT06528665View on ClinicalTrials.gov

Determine PK Profiles of Ozanimod and Its' Major Metabolites in Healthy Subjects

RecruitingOBSERVATIONAL
Enrollment

24

Participants

Timeline

Start Date

February 10, 2025

Primary Completion Date

March 16, 2025

Study Completion Date

April 16, 2025

Conditions
Multiple SclerosisUlcerative Colitis
Interventions
DRUG

ZEPOSIA® indicated for the treatment of: Relapsing forms of multiple sclerosis, and active ulcerative colitis in adults

"ZEPOSIA®~* Titration is required for treatment initiation.~* The recommended maintenance dosage is 0.92 mg orally once daily.~* If a dose is missed within the first 2 weeks of treatment, reinitiate with the titration regimen. If a dose is missed after the first 2 weeks of treatment, continue treatment as planned."

Trial Locations (1)

68000

RECRUITING

Hospital Ampang, Ampang

All Listed Sponsors
lead

Corium Innovations, Inc.

INDUSTRY